Parents of children with spinal muscular atrophy (SMA), a rare disease, welcomed the announcement by the Indian pharma ...

The company said it has decided to price its version of Risdiplam product at Rs 15,900, and further added that it intends to ...

Affordable generic version of SMA drug Risdiplam soon available in India, offering hope to patients and activists.

Natco Pharma updates on Risdiplam launch in India, Delhi High Court denies Roche's injunction plea, pricing set at ₹15,900.

The Supreme Court will review the Rs 50 lakh cap on the central government's aid for treating rare diseases like SMA. The ...

FDA-approved treatments for spinal muscular atrophy differ in their mechanisms of action, safety profiles, and administration ...

The stock rose 2.95 per cent to hit a high of Rs 789. It was last seen trading 1.44 per cent up at Rs 777.45. At this price, ...

The Supreme Court on Tuesday decided to examine pleas challenging the Rs 50 lakh cap on Centre's assistance for treating ...

It was submitted that why can't the Indian government negotiate with Roche to make the medicine for the rare disorder ...

The Supreme Court has sought responses from the Centre and pharmaceutical giant Roche on why their SMA treatment drug, ...

Supreme Court examines pleas challenging 50 lakh cap on Centre's assistance for treating rare diseases like SMA.

The Supreme Court of India seeks responses from the Centre and Roche on making the spinal muscular atrophy treatment drug ...